ADC Therapeutics SA Company Analysis & Research

Company Overview

Founded: 2011. Headquarters: Epalinges, Switzerland. Revenue: $185.4M (2023). Employees: 263. Market Cap: $518M. Ticker: ADCT (NYSE).

Industry

Biopharmaceuticals / Oncology - Antibody-Drug Conjugates (ADCs)

Cyborg Score: 5/10 — Mixed

ADC Therapeutics presents a balanced risk-reward profile as a validated oncology innovator with commercial product but near-term profitability challenges requiring successful pipeline advancement and market expansion.

ADC Therapeutics has achieved regulatory approval and commercialization of ZYNLONTA, demonstrating scientific validation and market traction. However, the company faces challenges including significant operating losses, declining market capitalization, and revenue pressures that create execution risk despite a promising pipeline.

Key Strategic Insights for ADC Therapeutics SA

• Flagship product ZYNLONTA holds FDA accelerated approval for DLBCL with ongoing Phase 3 expansion (LOTIS-5) into earlier treatment lines and additional lymphoma indications
• Market capitalization declined to $518M (Feb 2026) from IPO price of $17/share (May 2020), reflecting biotech sector volatility and execution challenges
• Pipeline includes ADCT-602 for acute lymphoblastic leukemia and multiple solid tumor candidates (Claudin-6, PSMA, NaPi2b, ASCT2) addressing distinct oncology segments
• Global operations and regulatory approvals in US, EU, and China provide geographic diversification and international revenue potential beyond US market

Recent Developments

• (Feb 2026) Stock price at $4.18 with market cap of $518M, reflecting recent market positioning
• (2023) Reported $185.4M revenue and $246.3M net loss; $272.6M cash position supports pipeline advancement
• (Ongoing) LOTIS-5 Phase 3 trial expanding ZYNLONTA into earlier DLBCL lines and indolent lymphomas including follicular and marginal zone lymphoma

Competitors & Competitive Landscape

• Aura Biosciences — Precision oncology using photodynamic therapy and other targeted approaches
• Seagen — Pioneer in antibody-drug conjugates for hematologic and solid tumors
• Multiple competitors in oncology biotech sector — Various approaches to hematologic malignancies and solid tumor treatment

ADC Therapeutics competes in the specialized antibody-drug conjugate space against other oncology biotech companies developing targeted cancer therapies. Key competitors include Aura Biosciences and other developers of hematological and solid tumor treatments. ADC Therapeutics differentiates through its validated PBD-based ADC platform, FDA-approved commercial product, and comprehensive pipeline targeting multiple tumor-associated antigens.

More Company Research

Full Company Research Reports

Looking for a more in-depth analysis of ADC Therapeutics SA? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.